The colorectal cancer diagnostics industry is consolidated in nature. The companies operating in this industry such as Qiagen N.V. are focusing their efforts on continuous product innovation in order to acquire substantial market share. For instance, in September 2022, Qiagen announced a strategic partnership with Neuron23, a biotechnology company to develop NGS based tests in companion diagnostic. The collaboration helped the company to enhance their R&D activities and build a strong brand image thereby enhancing overall business revenue.
Some of the eminent market participants operating in in the colorectal cancer diagnostics industry include: